Xenon Pharmaceuticals Inc.

This study tests whether XEN1101, taken alongside current seizure medications, can reduce the number of generalized tonic-clonic seizures (convulsions affecting the whole body). About 160 people aged 12 and older with these seizures will receive either XEN1101 or a placebo for se…

This Phase 3 trial tests whether XEN1101 (azetukalner) can safely reduce seizure frequency in people with focal-onset seizures. About 360 adults whose seizures aren't controlled by current medications will receive either XEN1101 or a placebo added to their existing treatment. The…

This study tests whether a new medication called azetukalner can reduce depression symptoms in adults with moderate-to-severe major depressive disorder. About 450 participants will receive either the drug or a placebo for 6 weeks. The main goal is to see if the drug improves mood…

This study tests an experimental drug called azetukalner in 450 adults with moderate-to-severe major depression. Participants take the drug or a placebo daily for 6 weeks to see if it reduces depression symptoms like low mood and loss of pleasure. The goal is to find a new treatm…

This Phase 3 trial tests whether a daily pill called azetukalner can safely reduce depression in people with bipolar I or II disorder. About 400 adults currently in a depressive episode will take either the drug or a placebo for 6 weeks. Researchers will measure mood changes usin…